Brief Summary: This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive…...
Leading Vasculitis Physician-Scientist Receives Covid-19 Vaccine
Dr. Peter Merkel, Director of the University of Pennsylvania Vasculitis Center and Co-Principal Investigator of the Vasculitis Patient-Powered Research Network, received his first dose of a COVID-19 vaccine just before New Year’s Eve. Dr. Merkel says “I am excited that the vaccine will become increasingly available to everyone, especially patients…...
